A innovator in chip-based bioanalysis technologies.

Peter Wagner, President and CEO of Zyomyx, Inc. ‘Now that we have achieved this significant milestone, we are actively engaging with select global product sales and distribution partners who might help us consider the Zyomyx check to market. This includes extra cell count applications in diagnostics and lifestyle science study beyond CD4 where a cheap, simple alternative to stream cytometry is desired.’.. CD4 Initiative selects Zyomyx’s CD4 POC technology as best for measuring CD4 T-cell count in HIV/AIDS patients Zyomyx, Inc., a innovator in chip-based bioanalysis technologies, today announced that its readerless CD4 point-of-treatment technology was selected by Imperial College London’s CD4 Initiative mainly because the best-performing POC test method for measuring CD4 T-cell count in HIV/Helps patients.Listed below are some surprising specifics on the purported developments in breast cancer recognition and treatment:Truth: Mammograms, as utilized for breasts cancer screening, frequently result in needless worry. According to one research published in the brand new England Journal of Medication, one third of the ladies screened over a 10 season period received a fake positive. Furthermore to harmful radiation, because the intro of mammographic screening, the incidence of a kind of breast cancers known as ductal carcinoma in situ has elevated by 328 percent. It really is postulated that over fifty % of this boost is because of mammography. According for some ongoing health practitioners, the considerable pressure positioned on the breast through the procedure could actually spread existing cancers cells, causing existing cancer cellular material to metastasize from the breasts tissue thus.